DBV Technologies | DBVT - Current Assets


DBV Technologies reported $212.94M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
DBV Technologies USD 212.94M 124.06M Dec/2025
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Galectin Therapeutics USD 27.29M 1.83M Jun/2024
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026